- Home
- IMMX vs ARQQ Comparison
IMMX vs ARQQ Comparison
Compare IMMX & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- ARQQ
- Stock Information
- Founded
- IMMX 2014
- ARQQ 2017
- Country
- IMMX United States
- ARQQ United Kingdom
- Employees
- IMMX N/A
- ARQQ N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- ARQQ Computer Software: Prepackaged Software
- Sector
- IMMX Health Care
- ARQQ Technology
- Exchange
- IMMX Nasdaq
- ARQQ Nasdaq
- Market Cap
- IMMX 61.1M
- ARQQ 598.3M
- IPO Year
- IMMX 2021
- ARQQ N/A
- Fundamental
- Price
- IMMX $2.55
- ARQQ $35.08
- Analyst Decision
- IMMX Strong Buy
- ARQQ Strong Buy
- Analyst Count
- IMMX 1
- ARQQ 1
- Target Price
- IMMX $7.00
- ARQQ $52.00
- AVG Volume (30 Days)
- IMMX 169.7K
- ARQQ 1.2M
- Earning Date
- IMMX 08-11-2025
- ARQQ 05-22-2025
- Dividend Yield
- IMMX N/A
- ARQQ N/A
- EPS Growth
- IMMX N/A
- ARQQ N/A
- EPS
- IMMX N/A
- ARQQ 0.48
- Revenue
- IMMX N/A
- ARQQ $241,000.00
- Revenue This Year
- IMMX N/A
- ARQQ $1,818.77
- Revenue Next Year
- IMMX N/A
- ARQQ N/A
- P/E Ratio
- IMMX N/A
- ARQQ $72.42
- Revenue Growth
- IMMX N/A
- ARQQ N/A
- 52 Week Low
- IMMX $1.26
- ARQQ $3.72
- 52 Week High
- IMMX $3.00
- ARQQ $52.79
- Technical
- Relative Strength Index (RSI)
- IMMX 61.17
- ARQQ 57.65
- Support Level
- IMMX $2.16
- ARQQ $32.80
- Resistance Level
- IMMX $2.31
- ARQQ $43.50
- Average True Range (ATR)
- IMMX 0.18
- ARQQ 4.26
- MACD
- IMMX 0.00
- ARQQ -0.38
- Stochastic Oscillator
- IMMX 92.59
- ARQQ 54.62
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.